Amaxa and Qiagen Announce Marketing Agreement

(Venlo, The Netherlands).

Amaxa has developed technology called Nucleofector as a tool for the transfection of siRNA oligonucleotides and siRNA vectors into primary cells, hard-to-transfect cells, and commonly used cell lines. Qiagen has developed high performance purity (HPP) grade siRNA oligonucleotides based on patented chemistry for effective and reproducible gene silencing. Qiagen is a supplier of oligonucleotide synthesis services and provides a large library of predeveloped siRNA molecules directed against common target genes, including cancer-related genes and the SARS coronavirus siRNA set.

"The combination of Qiagen's siRNA know-how with our ability to transfect suspension cell lines and primary cells with siRNA oligonucleotides enables us to offer our customers a complete package for the successful knock-down of specific genes,” said Rainer Christine, CEO of Amaxa.





Related Links:
Amaxa
Qiagen